Monotherapy Or Chemotherapy Adjunct: Pembrolizumab In Advanced NSCLC

Welcome to NewMedicalTerms, your ultimate guide to the explanations and definitions of the majority of medical terms you may see.

Monotherapy Or Chemotherapy Adjunct: Pembrolizumab In Advanced NSCLC Objectives To assess the effectiveness and safety of pembrolizumab monotherapy and in combination with chemotherapy in patients with advanced non–small-cell lung cancer (NSCLC).  Introduction Historically, patients with advanced NSCLC have a poor prognosis despite the use of platinum-based chemotherapy drugs. The 5-year relative survival rate of

Lung Cancer with Brain Metastasis After Late-Onset Bipolar Disorder: A Case Report

Welcome to NewMedicalTerms, your ultimate guide to the explanations and definitions of the majority of medical terms you may see.

Lung Cancer with Brain Metastasis After Late-Onset Bipolar Disorder: A Case Report Background Bipolar disorder is a multifactorial illness with uncertain etiology and geriatric new-onset manic episodes are highly associated with secondary organic causes. The presented case demonstrates the importance of excluding secondary causes during the entire disease course.  Overview Bipolar disorder is a

Anlotinib with Camrelizumab in Lung Cancer Treatment

Welcome to NewMedicalTerms, your ultimate guide to the explanations and definitions of the majority of medical terms you may see.

Anlotinib with Camrelizumab in Lung Cancer Treatment Background Checkpoint inhibitors (CPIs) and anti-angiogenic agents are emerging as potential novel treatment choices for advanced cancers including metastatic non-small-cell lung cancer (NSCLC). However, the combination of these two standard therapies has not been investigated in third-line or further-line treatment of patients with advanced NSCLC.

Inoperable locally advanced non-small cell lung cancer: Survival rates of Endostar, CCRT

Welcome to NewMedicalTerms, your ultimate guide to the explanations and definitions of the majority of medical terms you may see.

Inoperable locally advanced non-small cell lung cancer: Survival rates of Endostar, CCRT Inoperable locally advanced non-small cell lung cancer (NSCLC): An Introduction Accounting for approximately 80% of lung cancers, non-small cell lung cancer (NSCLC) is the most common subtype. Most NSCLC patients are diagnosed at an advanced stage with a mere 15-20%

Monotherapy Or Chemotherapy Adjunct: Pembrolizumab In Advanced NSCLC